Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
1st generation antihistamine derived from ethylenediamine with important sedative and antimuscarinic effects. Oral administration every 6 to 8 hours or intramuscular.
At the time of the last update, we did not find published data on its excretion in breast milk. Drug with little bibliographic support and marketed in very few countries (Eastern Europe, Mexico).
Monitor somnolence and adequate infant feeding.
It has an antiprolactin effect that could inhibit lactation in the first weeks after delivery.
Due to its sedative effect, bed-sharing with the infant is not recommended if this drug is being taken. (UNICEF 2018, 2017, 2017, 2014, 2014, 2013 and 2006, Landa 2012, ABM 2008)
Until we know more published data on this drug in relation to breastfeeding, safer known alternatives are preferable.